Exp Parasitol. 2017 Jul 31. pii: S0014-4894(17)30166-2. doi: 10.1016/j.exppara.2017.07.009. [Epub ahead of print]
Sanfelice RA1,
Machado LF1,
Bosqui LR1,
Miranda-Sapla MM1,
Tomiotto-Pellissier F1,
de Alcântara Dalevedo G1,
Ioris D1,
Reis GF2,
Panagio LA2,
Navarro IT3,
Bordignon J4,
Conchon-Costa I1,
Pavanelli WR1,
Almeida RS2,
Costa IN5.
Abstract
Due to the toxicity of conventional medication in toxoplasmosis, some drugs are being studied for treating this infection, such as statins, especially rosuvastatin compound, which is efficient in inhibiting the initial isoprenoid biosynthesis processes in humans and the parasite. The goal of this studywas to assess the activity of rosuvastatin in HeLa cells infectedwiththe RH strain of T. gondii. In the experiment, HeLa cells (1 × 105) were infected with tachyzoites of T. gondii (5 × 105). After the experimental infection, we assessed the number of infected cells and the amount of intracellular tachyzoites. In addition, culture supernatants were collected to determine the amount of cytokines by cytometric bead array. We observed that there was no cytotoxicity in the concentrations tested in this cell line. The effect of rosuvastatin showed a significant reduction in both the number of infected cells and the proliferation index of the intracellular parasite, when compared with the conventional treatment combining sulfadiazine and pyrimethamine for toxoplasmosis. There were also reduced levels of cytokines IL-6 and IL-17. Therefore, it was concluded that rosuvastatin exhibited antiproliferative activity. The data presented are significantto promote further studiesandthe search for alternative treatment for toxoplasmosis.
Copyright © 2017. Published by Elsevier Inc.
KEYWORDS:
Rosuvastatin; Statins; Toxoplasmosis
No comments:
Post a Comment